Pediatric RMS, especially the alveolar subtype with PAX3:FOXO1 or PAX7:FOXO1 fusions, often exhibits a notably immune-suppressing environment that impairs effective anti-tumor immune responses [16,17]. This evidence concerns the gene PAX3 and neoplasm.